Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accounts Payables: 2018-2025

  • China SXT Pharmaceuticals' Accounts Payables rose 468.01% to $7.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.3 million, marking a year-over-year increase of 468.01%. This contributed to the annual value of $7.3 million for FY2025, which is 468.01% up from last year.
  • As of Q1 2025, China SXT Pharmaceuticals' Accounts Payables stood at $7.3 million, which was up 468.01% from $1.3 million recorded in Q1 2024.
  • In the past 5 years, China SXT Pharmaceuticals' Accounts Payables registered a high of $7.3 million during Q1 2025, and its lowest value of $1.3 million during Q1 2024.
  • Its 3-year average for Accounts Payables is $3.3 million, with a median of $1.4 million in 2023.
  • In the last 5 years, China SXT Pharmaceuticals' Accounts Payables crashed by 60.96% in 2023 and then spiked by 468.01% in 2025.
  • Quarterly analysis of 5 years shows China SXT Pharmaceuticals' Accounts Payables stood at $3.0 million in 2021, then grew by 15.84% to $3.5 million in 2022, then crashed by 60.96% to $1.4 million in 2023, then fell by 7.14% to $1.3 million in 2024, then spiked by 468.01% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q1 2025, $1.3 million for Q1 2024, and $1.4 million during Q1 2023.